Scarica l'app Stockscreener
4.05
2.27%
0.09
Dopo l'orario di chiusura:
4.06
0.010
+0.25%
Precedente Chiudi:
$3.96
Aprire:
$3.98
Volume 24 ore:
516.90K
Relative Volume:
0.37
Capitalizzazione di mercato:
$277.62M
Reddito:
$380.79M
Utile/perdita netta:
$49.27M
Rapporto P/E:
-3.2661
EPS:
-1.24
Flusso di cassa netto:
$10.68M
1 W Prestazione:
-1.70%
1M Prestazione:
-22.56%
6M Prestazione:
+145.45%
1 anno Prestazione:
-70.67%
Intervallo 1D:
$3.96
$4.18
Intervallo di 1 settimana:
$3.78
$4.3995
Portata 52W:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Industria
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Confronta AMLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
4.05 | 277.62M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
XTX Topco Ltd Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding - Simply Wall St
Fmr LLC Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - AccessWire
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Drops By 5.2% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - AccessWire
Progressive Supranuclear Palsy Market Statistics Expected - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - AccessWire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Amylyx stock receives Buy rating from H.C. Wainwright, set for Phase 3 trial significance - Investing.com
4 Analysts Assess Amylyx Pharma: What You Need To Know - Inkl
Amylyx announces design of LUCIDITY clinical trial - Yahoo Finance
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia - Business Wire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Walleye Capital LLC - MarketBeat
Amylyx Pharmaceuticals chief medical officer sells $30,007 in stock By Investing.com - Investing.com Australia
Amylyx Pharmaceuticals chief medical officer sells $30,007 in stock - Investing.com
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
Alpha Wave Global LP Invests $2.17 Million in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
PTC halts development of ALS drug after trial miss - The Pharma Letter
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along - Seeking Alpha
Connor Clark & Lunn Investment Management Ltd. Has $2.85 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN
Goldman Sachs reiterates Neutral on Amylyx stock, target unchanged amid PBH market uncertainties - Investing.com Nigeria
Baird R W Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to Strong-Buy - MarketBeat
Baird Upgrades Amylyx Pharmaceuticals (AMLX) - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha
Robert W. Baird Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to "Outperform" - MarketBeat
Amylyx shares rise to Outperform rating as Baird projects strong PBH drug market impact - Investing.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance
Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Q3 2024 Financial Highlights - TipRanks
Amylyx Pharmaceuticals Inc. (AMLX) Quarterly 10-Q Report - Quartz
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amylyx Pharmaceuticals Inc Azioni (AMLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive Officer |
Nov 04 '24 |
Option Exercise |
1.57 |
63,690 |
99,993 |
3,184,259 |
| Klee Justin B. | Co-Chief Executive Officer |
Sep 30 '24 |
Sale |
3.20 |
18,589 |
59,429 |
3,120,569 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 30 '24 |
Sale |
3.20 |
18,589 |
59,414 |
3,220,569 |
| Bedrosian Camille L | Chief Medical Officer |
Sep 30 '24 |
Sale |
3.20 |
11,442 |
36,559 |
143,801 |
| Mazzariello Gina | Chief Legal Officer |
Sep 30 '24 |
Sale |
3.20 |
8,709 |
27,840 |
142,768 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 23 '24 |
Option Exercise |
1.57 |
1,857 |
2,915 |
3,239,158 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 12 '24 |
Option Exercise |
1.57 |
34,449 |
54,085 |
3,237,301 |
| FRATES JAMES M | Chief Financial Officer |
Sep 12 '24 |
Buy |
2.53 |
40,000 |
101,368 |
233,464 |
| Firestone Karen | Director |
Sep 05 '24 |
Buy |
2.13 |
50,000 |
106,590 |
55,000 |
| MILNE GEORGE M JR | Director |
Sep 03 '24 |
Buy |
2.20 |
100,000 |
219,800 |
858,571 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):